Display options
Share it on

J Pharmacopuncture. 2018 Dec;21(4):294-295. doi: 10.3831/KPI.2018.21.033. Epub 2018 Dec 31.

Immunomodulatory and Anti-Inflammatory Phytochemicals for the Treatment of Inflammatory Bowel Disease (IBD): - Turning Strong Rationale into Strong Evidence?.

Journal of pharmacopuncture

Hamid Reza Sodagari, Zahra Aryan, Amir Hossein Abdolghaffari, Nima Rezaei, Amirhossein Sahebkar

Affiliations

  1. Young Researchers and Elite Club, Karaj Branch, Islamic Azad University, Karaj, Iran.
  2. Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  3. Pediatric Respiratory Diseases Education and Research Network (PRDERN), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
  4. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  5. Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Tehran, Iran Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  6. Department of Pharmacology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.
  7. Department of Toxicology and Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  8. Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
  9. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
  10. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  11. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  12. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

PMID: 30671279 PMCID: PMC6333189 DOI: 10.3831/KPI.2018.21.033

[No abstract available.]

Keywords: Crohn’s disease; inflammatory bowel disease; phytochemicals

Conflict of interest statement

Conflict of interest The authors declare that there are no conflicts of interest.

References

  1. Mol Pharmacol. 2001 Sep;60(3):528-33 - PubMed
  2. Dig Dis Sci. 2005 Nov;50(11):2191-3 - PubMed
  3. Nat Rev Immunol. 2008 Jun;8(6):458-66 - PubMed
  4. Nat Genet. 2008 Aug;40(8):955-62 - PubMed
  5. Inflamm Bowel Dis. 2009 Jul;15(7):1090-100 - PubMed
  6. Mol Nutr Food Res. 2009 Jun;53(6):686-98 - PubMed
  7. Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18132-7 - PubMed
  8. Lancet Infect Dis. 2011 Sep;11(9):702-12 - PubMed
  9. Pharmacol Res. 2012 Sep;66(3):235-42 - PubMed
  10. Nat Rev Immunol. 2013 May;13(5):321-35 - PubMed
  11. Environ Toxicol Pharmacol. 2014 Mar;37(2):819-27 - PubMed
  12. Pharmacol Rep. 2014 Feb;66(1):169-73 - PubMed
  13. Microvasc Res. 2015 Jan;97:167-80 - PubMed
  14. Nutrients. 2016 Apr 09;8(4):211 - PubMed
  15. Nature. 2016 Dec 21;540(7634):S97 - PubMed

Publication Types